Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2012, Article ID 809164, 13 pages
http://dx.doi.org/10.1155/2012/809164
Review Article

PPARγ Ligands Regulate Noncontractile and Contractile Functions of Airway Smooth Muscle: Implications for Asthma Therapy

Department of Pharmacology, University of Melbourne, Parkville, VIC 3010, Australia

Received 6 February 2012; Accepted 12 June 2012

Academic Editor: Virender K. Rehan

Copyright © 2012 Chantal Donovan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach, WHO, Geneva, Switzerland, 2007.
  2. A. J. Woolcock, D. Dusser, and I. Fajac, “Severity of chronic asthma,” Thorax, vol. 53, no. 6, pp. 442–444, 1998. View at Google Scholar · View at Scopus
  3. A. L. Lazaar and R. A. Panettieri Jr., “Airway smooth muscle: a modulator of airway remodeling in asthma,” Journal of Allergy and Clinical Immunology, vol. 116, no. 3, pp. 488–496, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Ozier, B. Allard, I. Bara et al., “The pivotal role of airway smooth muscle in asthma pathophysiology,” Journal of Allergy, vol. 2011, Article ID 742710, 20 pages, 2011. View at Publisher · View at Google Scholar
  5. N. C. Thomson and M. Spears, “The influence of smoking on the treatment response in patients with asthma,” Current Opinion in Allergy and Clinical Immunology, vol. 5, no. 1, pp. 57–63, 2005. View at Google Scholar · View at Scopus
  6. J. W. Wilson and S. Hii, “The importance of the airway microvasculature in asthma,” Current Opinion in Allergy and Clinical Immunology, vol. 6, no. 1, pp. 51–55, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Camoretti-Mercado, “Targeting the airway smooth muscle for asthma treatment,” Translational Research, vol. 154, no. 4, pp. 165–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Zuyderduyn, M. B. Sukkar, A. Fust, S. Dhaliwal, and J. K. Burgess, “Treating asthma means treating airway smooth muscle cells,” European Respiratory Journal, vol. 32, no. 2, pp. 265–274, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. V. K. Rehan, K. Asotra, and J. S. Torday, “The effects of smoking on the developing lung: insights from a biologic model for lung development, homeostasis, and repair,” Lung, vol. 187, no. 5, pp. 281–289, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Benayoun, S. Letuve, A. Druilhe et al., “Regulation of peroxisome proliferator-activated receptor γ expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 8, pp. 1487–1494, 2001. View at Google Scholar · View at Scopus
  11. A. Werman, A. Hollenberg, G. Solanes, C. Bjørbæk, A. J. Vidal-Puig, and J. S. Flier, “Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor γ (PPARγ). Differential activity of PPARγ1 and -2 isoforms and influence of insulin,” The Journal of Biological Chemistry, vol. 272, no. 32, pp. 20230–20235, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Adams, M. J. Reginato, D. Shao, M. A. Lazar, and V. K. Chatterjee, “Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site,” The Journal of Biological Chemistry, vol. 272, no. 8, pp. 5128–5132, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. R. T. Nolte, G. B. Wisely, S. Westin et al., “Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-γ,” Nature, vol. 395, no. 6698, pp. 137–143, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. T. J. Heppner, A. D. Bonev, D. M. Eckman, M. F. Gomez, G. V. Petkov, and M. T. Nelson, “Novel PPARγ agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries,” Pharmacology, vol. 73, no. 1, pp. 15–22, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Wang, W. W. Porter, N. Suh et al., “A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor γ,” Molecular Endocrinology, vol. 14, no. 10, pp. 1550–1556, 2000. View at Google Scholar · View at Scopus
  17. B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy-Δ12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ,” Cell, vol. 83, no. 5, pp. 803–812, 1995. View at Google Scholar · View at Scopus
  18. J. E. Ward, H. Gould, T. Harris, J. V. Bonacci, and A. G. Stewart, “PPARγ ligands, 15-deoxy-Δ12,14-prostaglandin J2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms,” British Journal of Pharmacology, vol. 141, no. 3, pp. 517–525, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. L. A. Moraes, L. Piqueras, and D. Bishop-Bailey, “Peroxisome proliferator-activated receptors and inflammation,” Pharmacology and Therapeutics, vol. 110, no. 3, pp. 371–385, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Schoonjans, B. Staels, and J. Auwerx, “The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation,” Biochimica et Biophysica Acta, vol. 1302, no. 2, pp. 93–109, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Pang, M. Nie, L. Corbett, and A. J. Knox, “Cyclooxygenase-2 expression by nonsteroidal anti-inflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors,” Journal of Immunology, vol. 170, no. 2, pp. 1043–1051, 2003. View at Google Scholar · View at Scopus
  23. S. Ghisletti, W. Huang, S. Ogawa et al., “Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARγ,” Molecular Cell, vol. 25, no. 1, pp. 57–70, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. L. M. Leesnitzer, D. J. Parks, R. K. Bledsoe et al., “Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662,” Biochemistry, vol. 41, no. 21, pp. 6640–6650, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Honda, P. Marquillies, M. Capron, and D. Dombrowicz, “Peroxisome proliferator-activated receptor γ is expressed in airways and inhibits features of airway remodeling in a mouse asthma model,” Journal of Allergy and Clinical Immunology, vol. 113, no. 5, pp. 882–888, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. H. A. Burgess, L. E. Daugherty, T. H. Thatcher et al., “PPARγ agonists inhibit TGF-β induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis,” American Journal of Physiology, vol. 288, no. 6, pp. L1146–L1153, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. K. S. Lee, S. J. Park, P. H. Hwang et al., “PPAR-gamma modulates allergic inflammation through up-regulation of PTEN,” FASEB Journal, vol. 19, no. 8, pp. 1033–1035, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. N. J. Smith, L. A. Stoddart, N. M. Devine, L. Jenkins, and G. Milligan, “The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1,” The Journal of Biological Chemistry, vol. 284, no. 26, pp. 17527–17539, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Ialenti, G. Grassia, P. Di Meglio, P. Maffia, M. Di Rosa, and A. Ianaro, “Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway,” Molecular Pharmacology, vol. 67, no. 5, pp. 1620–1628, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Chinetti, J. C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation,” Inflammation Research, vol. 49, no. 10, pp. 497–505, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. D. S. Straus, G. Pascual, M. Li et al., “15-deoxy-Δ12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, pp. 4844–4849, 2000. View at Google Scholar
  32. H. Cho and H. H. Tai, “Thiazolidinediones as a novel class of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors,” Archives of Biochemistry and Biophysics, vol. 405, no. 2, pp. 247–251, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. H. E. Ferguson, T. H. Thatcher, K. C. Olsen et al., “Peroxisome proliferator-activated receptor-γ ligands induce heme oxygenase-1 in lung fibroblasts by a PPARγ-independent, glutathione-dependent mechanism,” American Journal of Physiology, vol. 297, no. 5, pp. L912–L919, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. S. G. Harris, R. S. Smith, and R. P. Phipps, “15-Deoxy-Δ12,14-PGJ2 induces IL-8 production in human T cells by a mitogen-activated protein kinase pathway,” Journal of Immunology, vol. 168, no. 3, pp. 1372–1379, 2002. View at Google Scholar · View at Scopus
  35. K. M. Patel, K. L. Wright, P. Whittaker, P. Chakravarty, M. L. Watson, and S. G. Ward, “Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPARγ agonists: evidence for disparate functional effects which are independent of NF-κB and PPARγ,” Cellular Signalling, vol. 17, no. 9, pp. 1098–1110, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. N. K. LeBrasseur, M. Kelly, T. S. Tsao et al., “Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues,” American Journal of Physiology, vol. 291, no. 1, pp. E175–E181, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Asano, T. Nakajima, K. Iwasawa et al., “Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells,” British Journal of Pharmacology, vol. 128, no. 3, pp. 673–683, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. H. Fan, H. Chen, A. Natarajan et al., “Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 10, pp. 2547–2550, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Caddy, N. Singh, L. Atkin et al., “Rosiglitazone transiently disturbs calcium homeostasis in monocytic cells,” Biochemical and Biophysical Research Communications, vol. 366, no. 1, pp. 149–155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Kono, G. Ahn, D. R. Moss et al., “PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress,” Molecular Endocrinology, vol. 26, no. 2, pp. 257–271, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. J. E. Ward and X. Tan, “Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease,” PPAR Research, vol. 2007, Article ID 14983, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. J. T. Huang, J. S. Welch, M. Ricote et al., “Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase,” Nature, vol. 400, no. 6742, pp. 378–382, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. A. C. C. Wang, X. Dai, B. Luu, and D. J. Conrad, “Peroxisome proliferator-activated receptor-γ regulates airway epithelial cell activation,” American Journal of Respiratory Cell and Molecular Biology, vol. 24, no. 6, pp. 688–693, 2001. View at Google Scholar · View at Scopus
  44. G. Chinetti, S. Griglio, M. Antonucci et al., “Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages,” The Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Sugiyama, T. Nonaka, T. Kishimoto, K. Komoriya, K. Tsuji, and T. Nakahata, “Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation,” European Journal of Immunology, vol. 30, no. 12, pp. 3363–3370, 2000. View at Google Scholar · View at Scopus
  47. S. R. Kim, K. S. Lee, H. S. Park et al., “Involvement of IL-10 in peroxisome proliferator-activated receptor γ-mediated anti-inflammatory response in asthma,” Molecular Pharmacology, vol. 68, no. 6, pp. 1568–1575, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Liu, R. Sakurai, E. M. O'Roark, N. J. Kenyon, J. S. Torday, and V. K. Rehan, “PPARγ agonist rosiglitazone prevents perinatal nicotine exposure-induced asthma in rat offspring,” American Journal of Physiology, vol. 300, no. 5, pp. L710–L717, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. V. K. Rehan, Y. Wang, S. Sugano et al., “In utero nicotine exposure alters fetal rat lung alveolar type II cell proliferation, differentiation, and metabolism,” American Journal of Physiology, vol. 292, no. 1, pp. L323–L333, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Y. Lau, B. G. Oliver, L. M. Moir, J. L. Black, and J. K. Burgess, “Differential expression of peroxisome proliferator activated receptor γ and cyclin D1 does not affect proliferation of asthma-and non-asthma-derived airway smooth muscle cells,” Respirology, vol. 15, no. 2, pp. 303–312, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. S. A. Shore and P. E. Moore, “Effects of cytokines on contractile and dilator responses of airway smooth muscle,” Clinical and Experimental Pharmacology and Physiology, vol. 29, no. 10, pp. 859–866, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. O. Tliba and R. A. Panettieri, “Noncontractile functions of airway smooth muscle cells in asthma,” Annual Review of Physiology, vol. 71, pp. 509–535, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. R. A. Panettieri Jr., M. I. Kotlikoff, W. T. Gerthoffer et al., “Airway smooth muscle in bronchial tone, inflammation, and remodeling: basic knowledge to clinical relevance,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 3, pp. 248–252, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. M. A. Saunders, J. A. Mitchell, P. M. Seldon et al., “Release of granulocyte-macrophage colony stimulating factor by human cultured airway smooth muscle cells: suppression by dexamethasone,” British Journal of Pharmacology, vol. 120, no. 4, pp. 545–546, 1997. View at Publisher · View at Google Scholar · View at Scopus
  55. H. J. Patel, M. G. Belvisi, D. Bishop-Bailey, M. H. Yacoub, and J. A. Mitchell, “Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy,” Journal of Immunology, vol. 170, no. 5, pp. 2663–2669, 2003. View at Google Scholar · View at Scopus
  56. K. F. Chung, H. J. Patel, E. J. Fadlon et al., “Induction of eotaxin expression and release from human airway smooth muscle cells by IL-1β and TNFα: effects of IL-10 and corticosteroids,” British Journal of Pharmacology, vol. 127, no. 5, pp. 1145–1150, 1999. View at Publisher · View at Google Scholar · View at Scopus
  57. M. P. Hallsworth, L. M. Moir, D. Lai, and S. J. Hirst, “Inhibitors of mitogen-activated protein kinases differentially regulate eosinophil-activating cytokine release from human airway smooth muscle,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 4, pp. 688–697, 2001. View at Google Scholar · View at Scopus
  58. S. McKay, S. J. Hirst, M. Bertrand-De Haas et al., “Tumor necrosis factor-α enhances mRNA expression and secretion of interleukin-6 in cultured human airway smooth muscle cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 23, no. 1, pp. 103–111, 2000. View at Google Scholar · View at Scopus
  59. M. L. Watson, S. P. Grix, N. J. Jordan et al., “Interleukin 8 and monocyte chemoattractant protein 1 production by cultured human airway smooth muscle cells,” Cytokine, vol. 10, no. 5, pp. 346–352, 1998. View at Publisher · View at Google Scholar · View at Scopus
  60. A. J. Knox, L. Corbett, J. Stocks, E. Holland, Y. M. Zhu, and L. Pang, “Human airway smooth muscle cells secrete vascular endothelial growth factor: up-regulation by bradykinin via a protein kinase C and prostanoid-dependent mechanism,” FASEB Journal, vol. 15, no. 13, pp. 2480–2488, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. Amrani and R. A. Panettieri Jr., “Cytokines induce airway smooth muscle cell hyperresponsiveness to contractile agonists,” Thorax, vol. 53, no. 8, pp. 713–716, 1998. View at Google Scholar · View at Scopus
  62. M. Nie, L. Corbett, A. J. Knox, and L. Pang, “Differential regulation of chemokine expression by peroxisome proliferator-activated receptor γ agonists: interactions with glucocorticoids and β2-agonists,” The Journal of Biological Chemistry, vol. 280, no. 4, pp. 2550–2561, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Zhu, L. Flynt, S. Ghosh et al., “Anti-inflammatory effects of thiazolidinediones in human airway smooth muscle cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 1, pp. 111–119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. N. Lazzeri, M. G. Belvisi, H. J. Patel, M. H. Yacoub, K. F. Chung, and J. A. Mitchell, “Effects of prostaglandin E2 and cAMP elevating drugs on GM-CSF release by cultured human airway smooth muscle cells relevance to asthma therapy,” American Journal of Respiratory Cell and Molecular Biology, vol. 24, no. 1, pp. 44–48, 2001. View at Google Scholar · View at Scopus
  65. M. Ebina, T. Takahashi, T. Chiba, and M. Motomiya, “Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma: a 3-D morphometric study,” American Review of Respiratory Disease, vol. 148, no. 3, pp. 720–726, 1993. View at Google Scholar · View at Scopus
  66. E. C. Gabazza, O. Taguchi, S. Tamaki et al., “Thrombin in the airways of asthmatic patients,” Lung, vol. 177, no. 4, pp. 253–262, 1999. View at Publisher · View at Google Scholar · View at Scopus
  67. A. E. Redington, W. R. Roche, J. Madden et al., “Basic fibroblast growth factor in asthma: measurement in bronchoalveolar lavage fluid basally and following allergen challenge,” Journal of Allergy and Clinical Immunology, vol. 107, no. 2, pp. 384–387, 2001. View at Publisher · View at Google Scholar · View at Scopus
  68. D. Fernandes, E. Guida, V. Koutsoubos et al., “Glucocorticoids inhibit proliferation, cyclin D1 expression, and retinoblastoma protein phosphorylation, but not activity of the extracellular-regulated kinases in human cultured airway smooth muscle,” American Journal of Respiratory Cell and Molecular Biology, vol. 21, no. 1, pp. 77–88, 1999. View at Google Scholar · View at Scopus
  69. A. M. Freyer, S. R. Johnson, and I. P. Hall, “Effects of growth factors and extracellular matrix on survival of human airway smooth muscle cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 25, no. 5, pp. 569–576, 2001. View at Google Scholar · View at Scopus
  70. P. R. A. Johnson, M. Roth, M. Tamm et al., “Airway smooth muscle cell proliferation is increased in asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 3, pp. 474–477, 2001. View at Google Scholar · View at Scopus
  71. M. Roth, P. R. A. Johnson, P. Borger et al., “Dysfunctional interaction of C/EBPα and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells,” The New England Journal of Medicine, vol. 351, no. 6, pp. 560–574, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. B. B. Araujo, M. Dolhnikoff, L. F. F. Silva et al., “Extracellular matrix components and regulators in the airway smooth muscle in asthma,” European Respiratory Journal, vol. 32, no. 1, pp. 61–69, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. A. E. Redington, J. Madden, A. J. Frew et al., “Transforming growth factor-β1 in asthma: measurement in bronchoalveolar lavage fluid,” American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 2, pp. 642–647, 1997. View at Google Scholar · View at Scopus
  74. J. E. Ward and S. J. Hirst, “Airway smooth muscle regulation of matrix proteins and interactions with the extracellular matrix,” Airway Smooth Muscle Biology and Pharmacology in Airways Disease, pp. 105–126, 2007. View at Google Scholar
  75. J. K. Burgess, B. G. G. Oliver, M. H. Poniris et al., “A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro,” Journal of Allergy and Clinical Immunology, vol. 118, no. 3, pp. 649–657, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. X. Tan, H. Dagher, C. A. Hutton, and J. E. Bourke, “Effects of PPARγ ligands on TGF-β1-induced epithelial-mesenchymal transition in alveolar epithelial cells,” Respiratory Research, vol. 11, article 21, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Hetzel, D. Walcher, M. Grüb, H. Bach, V. Hombach, and N. Marx, “Inhibition of MMP-9 expression by PPARγ activators in human bronchial epithelial cells,” Thorax, vol. 58, no. 9, pp. 778–783, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. T. R. Bai and D. A. Knight, “Structural changes in the airways in asthma: observations and consequences,” Clinical Science, vol. 108, no. 6, pp. 463–477, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. R. J. Bischof, J. E. Bourke, S. J. Hirst, E. N. T. Meeusen, K. J. Snibson, and J. Van Der Velden, “Measurement and impact of remodeling in the lung: airway neovascularization in asthma,” Proceedings of the American Thoracic Society, vol. 6, no. 8, pp. 673–677, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. S. R. Bailey, S. Boustany, J. K. Burgess et al., “Airway vascular reactivity and vascularisation in human chronic airway disease,” Pulmonary Pharmacology and Therapeutics, vol. 22, no. 5, pp. 417–425, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. D. E. Simcock, V. Kanabar, G. W. Clarke et al., “Induction of angiogenesis by airway smooth muscle from patients with asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 5, pp. 460–468, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Jozkowicz, H. Was, H. Taha et al., “15d-PGJ2 upregulates synthesis of IL-8 in endothelial cells through induction of oxidative stress,” Antioxidants and Redox Signaling, vol. 10, no. 12, pp. 2035–2046, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. K. Yamakawa, M. Hosoi, H. Koyama et al., “Peroxisome proliferator-activated receptor-γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells,” Biochemical and Biophysical Research Communications, vol. 271, no. 3, pp. 571–574, 2000. View at Publisher · View at Google Scholar · View at Scopus
  84. C. P. Byung, D. Thapa, S. L. Jong, S. Y. Park, and J. A. Kim, “Troglitazone inhibits vascular endothelial growth factor-induced angiogenic signaling via suppression of reactive oxygen species production and extracellular signal-regulated kinase phosphorylation in endothelial cells,” Journal of Pharmacological Sciences, vol. 111, no. 1, pp. 1–12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. C. G. McVicker, S. Y. Leung, V. Kanabar et al., “Repeated allergen inhalation induces cytoskeletal remodeling in smooth muscle from rat bronchioles,” American Journal of Respiratory Cell and Molecular Biology, vol. 36, no. 6, pp. 721–727, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. L. M. Moir, S. Y. Leung, P. R. Eynott et al., “Repeated allergen inhalation induces phenotypic modulation of smooth muscle in bronchioles of sensitized rats,” American Journal of Physiology, vol. 284, no. 1, pp. L148–L159, 2003. View at Google Scholar · View at Scopus
  87. V. K. Rehan, R. Sakurai, and J. S. Torday, “Thirdhand smoke: a new dimension to the effects of cigarette smoke on the developing lung,” American Journal of Physiology, vol. 301, no. 1, pp. 1–8, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. K. Mahn, O. O. Ojo, G. Chadwick, P. I. Aaronson, J. P. T. Ward, and T. H. Lee, “Ca2+ homeostasis and structural and functional remodelling of airway smooth muscle in asthma,” Thorax, vol. 65, no. 6, pp. 547–552, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. K. Mahn, S. J. Hirst, S. Ying et al., “Diminished sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) expression contributes to airway remodelling in bronchial asthma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 26, pp. 10775–10780, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. V. Randriamboavonjy, F. Pistrosch, B. Bölck et al., “Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and μ-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone,” Circulation, vol. 117, no. 1, pp. 52–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. P. J. Henry, A. D'Aprile, G. Self, T. Hong, and T. S. Mann, “Inhibitors of prostaglandin transport and metabolism augment protease-activated receptor-2-mediated increases in prostaglandin E2 levels and smooth muscle relaxation in mouse isolated trachea,” Journal of Pharmacology and Experimental Therapeutics, vol. 314, no. 3, pp. 995–1001, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Trifilieff, A. Bench, M. Hanley, D. Bayley, E. Campbell, and P. Whittaker, “PPAR-α and -γ but not -δ agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-κB-independent effect,” British Journal of Pharmacology, vol. 139, no. 1, pp. 163–171, 2003. View at Publisher · View at Google Scholar · View at Scopus
  93. K. S. Lee, S. R. Kim, S. J. Park et al., “Peroxisome proliferator activated receptor-γ modulates reactive oxygen species generation and activation of nuclear factor-κB and hypoxia-inducible factor 1α in allergic airway disease of mice,” Journal of Allergy and Clinical Immunology, vol. 118, no. 1, pp. 120–127, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. G. Woerly, K. Honda, M. Loyens et al., “Peroxisome proliferator-activated receptors α and γ down-regulate allergic inflammation and eosinophil activation,” Journal of Experimental Medicine, vol. 198, no. 3, pp. 411–421, 2003. View at Publisher · View at Google Scholar · View at Scopus
  95. C. K. Rhee, S. Y. Lee, J. Y. Kang et al., “Effect of peroxisome proliferator-activated receptor-gamma on airway smooth muscle thickening in a murine model of chronic asthma,” International Archives of Allergy and Immunology, vol. 148, no. 4, pp. 289–296, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. J. Bates, C. Irvin, V. Brusasco et al., “The use and misuse of Penh in animal models of lung disease,” American Journal of Respiratory Cell and Molecular Biology, vol. 31, no. 3, pp. 373–374, 2004. View at Google Scholar · View at Scopus
  97. S. J. Park, K. S. Lee, S. R. Kim et al., “Peroxisome proliferator-activated receptor γ agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation,” Journal of Immunology, vol. 183, no. 5, pp. 3259–3267, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. J. E. Ward, D. J. Fernandes, C. C. Taylor, J. V. Bonacci, L. Quan, and A. G. Stewart, “The PPARγ ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation,” Pulmonary Pharmacology and Therapeutics, vol. 19, no. 1, pp. 39–46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. H. Hammad, H. J. De Heer, T. Soullié et al., “Activation of peroxisome proliferator-activated receptor-γ in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma,” American Journal of Pathology, vol. 164, no. 1, pp. 263–271, 2004. View at Google Scholar · View at Scopus
  100. C. Mueller, V. Weaver, J. P. Vanden Heuvel, A. August, and M. T. Cantorna, “Peroxisome proliferator-activated receptor γ ligands attenuate immunological symptoms of experimental allergic asthma,” Archives of Biochemistry and Biophysics, vol. 418, no. 2, pp. 186–196, 2003. View at Publisher · View at Google Scholar · View at Scopus
  101. R. K. Kumar, C. Herbert, and P. S. Foster, “The “ classical” ovalbumin challenge model of asthma in mice,” Current Drug Targets, vol. 9, no. 6, pp. 485–494, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. J. C. Kips, G. P. Anderson, J. J. Fredberg et al., “Murine models of asthma,” European Respiratory Journal, vol. 22, pp. 374–382, 2003. View at Google Scholar
  103. P. Delerive, J. C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors in inflammation control,” Journal of Endocrinology, vol. 169, no. 3, pp. 453–459, 2001. View at Publisher · View at Google Scholar · View at Scopus
  104. S. W. Chung, B. Y. Kang, S. H. Kim, D. Cho, G. Trinchieri, and T. S. Kim, “Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-γ and nuclear factor-κB,” The Journal of Biological Chemistry, vol. 275, no. 42, pp. 32681–32687, 2000. View at Google Scholar · View at Scopus
  105. S. Fogli, S. Pellegrini, B. Adinolfi et al., “Rosiglitazone reverses salbutamol-induced β2-adrenoceptor tolerance in airway smooth muscle,” British Journal of Pharmacology, vol. 162, no. 2, pp. 378–391, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. P. J. Barnes, “Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids,” European Respiratory Journal, vol. 19, no. 1, pp. 182–191, 2002. View at Publisher · View at Google Scholar · View at Scopus
  107. P. R. Cooper and R. A. Panettieri, “Steroids completely reverse albuterol-induced β2-adrenergic receptor tolerance in human small airways,” Journal of Allergy and Clinical Immunology, vol. 122, no. 4, pp. 734–740, 2008. View at Publisher · View at Google Scholar · View at Scopus
  108. D. Shahin, E. E. Toraby, H. Abdel-Malek, V. Boshra, A. Z. Elsamanoudy, and D. Shaheen, “Effect of peroxisome proliferator-activated receptor gamma agonist (pioglitazone) and methotrexate on disease activity in rheumatoid arthritis (experimental and clinical study),” Clinical Medicine Insights, vol. 4, pp. 1–10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  109. J. Kohlroser, J. Mathai, J. Reichheld, B. F. Banner, and H. L. Bonkovsky, “Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States food and drug administration,” American Journal of Gastroenterology, vol. 95, no. 1, pp. 272–276, 2000. View at Publisher · View at Google Scholar · View at Scopus
  110. S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” The New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, 2007. View at Google Scholar · View at Scopus
  111. Y. Hashimoto and K. Nakahara, “Improvement of asthma after administration of pioglitazone,” Diabetes Care, vol. 25, no. 2, p. 401, 2002. View at Google Scholar · View at Scopus
  112. D. B. Richards, P. Bareille, E. L. Lindo, D. Quinn, and S. N. Farrow, “Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: a randomised controlled trial,” Respiratory Medicine, vol. 104, no. 5, pp. 668–674, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Spears, I. Donnelly, L. Jolly et al., “Bronchodilatory effect of the PPAR-γ agonist rosiglitazone in smokers with asthma,” Clinical Pharmacology and Therapeutics, vol. 86, no. 1, pp. 49–53, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. M. G. Belvisi and J. A. Mitchell, “Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease,” British Journal of Pharmacology, vol. 158, no. 4, pp. 994–1003, 2009. View at Publisher · View at Google Scholar · View at Scopus